Abstract

BackgroundGlaucoma is a leading cause of blindness. Early detection is advocated but there is insufficient evidence from randomized controlled trials (RCTs) to inform health policy on population screening. Primarily, there is no agreed screening intervention. For a screening programme, agreement is required on the screening tests to be used, either individually or in combination, the person to deliver the test and the location where testing should take place. This study aimed to use ophthalmologists (who were experienced glaucoma subspecialists), optometrists, ophthalmic nurses and patients to develop a reduced set of potential screening tests and testing arrangements that could then be explored in depth in a further study of their feasibility for evaluation in a glaucoma screening RCT.MethodsA two-round Delphi survey involving 38 participants was conducted. Materials were developed from a prior evidence synthesis. For round one, after some initial priming questions in four domains, specialists were asked to nominate three screening interventions, the intervention being a combination of the four domains; target population, (age and higher risk groups), site, screening test and test operator (provider). More than 250 screening interventions were identified. For round two, responses were condensed into 72 interventions and each was rated by participants on a 0-10 scale in terms of feasibility.ResultsUsing a cut-off of a median rating of feasibility of ≥5.5 as evidence of agreement of intervention feasibility, six interventions were identified from round 2. These were initiating screening at age 50, with a combination of two or three screening tests (varying combinations of tonometry/measures of visual function/optic nerve damage) organized in a community setting with an ophthalmic trained technical assistant delivering the tests. An alternative intervention was a ‘glaucoma risk score’ ascertained by questionnaire. The advisory panel recommended that further exploration of the feasibility of screening higher risk populations and detailed specification of the screening tests was required.ConclusionsWith systematic use of expert opinions, a shortlist of potential screening interventions was identified. Views of users, service providers and cost-effectiveness modeling are now required to identify a feasible intervention to evaluate in a future glaucoma screening trial.

Highlights

  • Glaucoma is a leading cause of blindness

  • A population screening programme for Open Angle Glaucoma (OAG) has been proposed as a policy to reduce the burden of glaucoma; before a screening programme is introduced robust evidence from high quality randomized controlled trials (RCTs) is required to demonstrate that any benefits of screening on reducing sight loss outweigh any potential harms and that this is cost effective [5]

  • This study has used an established method for the systematic use of expert opinion, informed by prior Health Technology Assessment reviews [4,6,7]

Read more

Summary

Introduction

Detection is advocated but there is insufficient evidence from randomized controlled trials (RCTs) to inform health policy on population screening. Glaucoma is a chronic progressive eye disease and is the leading cause of irreversible blindness worldwide [1]. OAG is asymptomatic until advanced stages of the disease but if identified early, treatment can be relatively effective at reducing the rate of progression [3]. A population screening programme for OAG has been proposed as a policy to reduce the burden of glaucoma; before a screening programme is introduced robust evidence from high quality randomized controlled trials (RCTs) is required to demonstrate that any benefits of screening on reducing sight loss outweigh any potential harms and that this is cost effective [5]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call